<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02297243</url>
  </required_header>
  <id_info>
    <org_study_id>SLS-US-02</org_study_id>
    <nct_id>NCT02297243</nct_id>
  </id_info>
  <brief_title>Sinopsys Lacrimal Stent Indicated for Sinus Irrigation</brief_title>
  <acronym>SLS</acronym>
  <official_title>The Sinopsys Lacrimal Stent Indicated for Sinus Irrigation Via Transcaruncular Ethmoid Sinus Access in Patients With Moderate to Severe Chronic Rhinosinusitis With Ethmoid Sinus Involvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinopsys Surgical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinopsys Surgical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect preliminary clinical data related to the safety and&#xD;
      performance of the Sinopsys Lacrimal Stent.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For purposes of this clinical study, the Sinopsys Lacrimal Stent is intended to provide a&#xD;
      means of administering saline sinus irrigation via a transcaruncular-ethmoid sinus access in&#xD;
      patients with moderate to severe chronic rhinosinusitis with ethmoid involvement. The purpose&#xD;
      of the administration of saline irrigation is to reduce the intensity of symptoms of chronic&#xD;
      rhinosinusitis in this patient population.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SNOT - 20</measure>
    <time_frame>18 Weeks</time_frame>
    <description>Chronic Rhinosinusitis symptoms as measured by SNOT-20 scores from baseline to 18 weeks follow-up (1, 4, 8, 12, and 18)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patency will be confirmed post procedure with passive flow through the SLS lumen by instilling 2-4 drops of sterile saline into the stented medial fornix and observing drainage.</measure>
    <time_frame>18 Weeks</time_frame>
    <description>Patients will be trained for self-administration of saline irrigation prior to the discharge home. Subjects will be instructed how to observe for stent patency and to report problems with flow to the Investigator.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: Incidence and occurrence of anticipated and unanticipated adverse events</measure>
    <time_frame>18 Weeks</time_frame>
    <description>Assessment of the incidence and occurrence of anticipated and unanticipated adverse events reported during the 18 weeks of the clinical study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lund-MacKay CT Scores</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Comparison of baseline and 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lund-Kennedy Nasal Endoscopy Scores</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Comparison of baseline and 12 weeks</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Ethmoid Sinusitis</condition>
  <arm_group>
    <arm_group_label>Sinopsys Lacrimal Stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sinopsys Lacrimal Stent</intervention_name>
    <description>The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.</description>
    <arm_group_label>Sinopsys Lacrimal Stent</arm_group_label>
    <other_name>SLS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. The Investigator has determined that the potential study subject has moderate to&#xD;
             severe chronic rhinosinusitis with ethmoid involvement and has followed at least&#xD;
             twelve (12) weeks of appropriate medical therapy prior to enrollment&#xD;
&#xD;
          2. Age ≥ 22 years&#xD;
&#xD;
          3. The potential study subject meets the American Academy of Otolaryngology - Head and&#xD;
             Neck Surgery (AAO-HNS) criteria for chronic rhinosinusitis 12 weeks or longer of two&#xD;
             or more of the following signs and symptoms:&#xD;
&#xD;
               -  Mucopurulent drainage (anterior, posterior, or both)&#xD;
&#xD;
               -  Nasal obstruction (congestion)&#xD;
&#xD;
               -  Facial pain-pressure-fullness, or&#xD;
&#xD;
               -  Decreased sense of smell&#xD;
&#xD;
             AND inflammation is documented by one or more of the following findings:&#xD;
&#xD;
               -  Purulent (not clear) mucus or edema in the middle meatus or ethmoid region&#xD;
&#xD;
               -  Polyps in nasal cavity or the middle meatus, and/or&#xD;
&#xD;
               -  Radiographic imaging showing inﬂammation of the paranasal sinuses&#xD;
&#xD;
          4. SNOT-20 total score ≥ 41&#xD;
&#xD;
          5. CT scan (coronal view) confirms inflammation / involvement of the ethmoid sinuses&#xD;
&#xD;
          6. CT scan (coronal view) confirms depth of olfactory fossa is Keros classification 1 or&#xD;
             2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Sinus opacification score of ≤ 8 or ≥ 18 measured using the CT derived Lund -- Mackay&#xD;
             scoring system&#xD;
&#xD;
          2. Isolated sinus disease evident on CT scan that would be unlikely to respond to target&#xD;
             ethmoid treatment (e.g., isolated sphenoid or frontal disease)&#xD;
&#xD;
          3. Severe polyposis defined as Grade III or Grade IV polyposis using the adapted scale&#xD;
             from Meltzer, 2006.&#xD;
&#xD;
          4. Prior ocular and/or sinus surgery for CRS&#xD;
&#xD;
          5. CT scan (coronal view) shows depth of olfactory fossa is Keros classification 3.&#xD;
&#xD;
          6. Prior surgical history, physical exam, nasal endoscopy and/or imaging studies suggest&#xD;
             significant distortion of the craniofacial anatomy thus prohibiting adequate placement&#xD;
             of the SLS&#xD;
&#xD;
          7. Presence of a sinonasal encepholocele as determined by CT scan&#xD;
&#xD;
          8. Presence of active HEENT infection including acute dacryocystitis&#xD;
&#xD;
          9. Febrile illness within 2 weeks and/or active pus from nose&#xD;
&#xD;
         10. Any sign of active ophthalmic disease, infection, or inflammation including the&#xD;
             presence of severe ocular surface inflammatory disease or signs and symptoms of &quot;dry&#xD;
             eye disease&quot; as determined by physical exam which could be exacerbated by the presence&#xD;
             of the device&#xD;
&#xD;
         11. Current use of topical medications for the eye to treat an active ophthalmic disease&#xD;
&#xD;
         12. HbA1c level of ≥ 7.5% at the time of screening, current chemotherapy, or other immune&#xD;
             compromised conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teena Augustino</last_name>
    <role>Study Director</role>
    <affiliation>Sinopsys Surgical Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Front Range ENT</name>
      <address>
        <city>Greeley</city>
        <state>Colorado</state>
        <zip>80634</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced ENT and Allergy</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <study_first_submitted>November 14, 2014</study_first_submitted>
  <study_first_submitted_qc>November 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2014</study_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Ethmoid Sinusitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

